Supplementary Figure 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

Key Points

• Bicistronic CAR T-cells control myeloma cells even with limited BCMA expression, demonstrating effectiveness against this cancer.
• Proliferation of CAR T-cells was notably observed when co-cultured with K562 cell lines expressing CD229 antigen.
• The effectiveness of CAR T-cells against myeloma was gauged over a 72-hour co-culture period with K562 cell lines.
• These findings suggest that targeting both BCMA and CD229 may enhance treatment options for myeloma patients.